Our lead product candidate, NP001, is a novel, proprietary investigational therapy that regulates activated macrophages associated with chronic neurologic diseases. NP001 transforms these activated, inflammatory macrophages, which are linked to neuronal damage, back to their normal, non-inflammatory state.

Neuraltus is investigating the use of NP001 in Alzheimer’s disease (AD) and frontotemporal dementia (FTD).